Clinical Trial Update: UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia [Phase 2]

View source ↗

Summary

Phase 2 trial UI-Romi-02 investigates adding romiplostim to standard of care for treatment-naive and relapsed or refractory severe aplastic anemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia

Drugs mentioned

• Romiplostim (romiplostim)

Snippet

Sponsor: Anjali Sharathkumar | Conditions: Aplastic Anemia | Phase 2 | Status: NOT_YET_RECRUITING